- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02306005
Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes. (InLipoDiab1)
Insulin Therapy and Quantitive and Qualitive Changes of Plasma Lipoproteins in Patients With Newly Diagnosed Type 1 Diabetes.
The aim of the study is to evaluate the effect of insulin therapy in patients with newly diagnosed type 1 diabetes on quantitative and qualitative changes of plasma lipoproteins, with particular emphasis on HDL metabolism, and analysis of the factors determining the effect of insulin therapy on lipid profile.The study is planned to cover a minimum of 100 people with newly diagnosed type 1 diabetes and lead prospective observation of this group (for a minimum of 5-10 years). Patients will be assessed: during the first hospitalization in the moment of diagnosis (prior to introduction of insulin treatment), after 3 weeks, after 6 months and after 12 months of insulin therapy. Further observations planned in the annual intervals. In addition, the study group will be under constant monitoring of metabolic evaluation every three months in the Outpatient Clinic.
During each follow-up will be assessed parameters evaluating the metabolism of plasma lipoprotein fractions and subfractions of HDL:
- The concentration of apolipoprotein: including A-I, A-II, A-IV, C (II and III), D and E
- Electrophoresis of plasma lipoproteins
- Electrophoresis of HDL
The activity of enzymes: acyltransferase lecithin: cholesterol (LCAT) and plasma lipoprotein lipase Moreover, evaluation of factors which may potentially modify the relation between insulin therapy and lipoproteins will be assessed
- Anthropometric data and markers of insulin resistance (such as BMI, waist-hip ratio, the estimated rate of glucose distribution, VAI index, body fat, blood pressure),
- Metabolic management of diabetes,,
- Protein glycation end products
- The concentration of plasma adipokines.
Expected impact of the research project on the development of science, civilization and society The obtained results allow to assess the impact of exogenous insulin on quantitative and qualitative changes and metabolism of lipoproteins in the serum of patients with type 1 diabetes. Understanding the etiopathogenesis of this phenomenon and the factors affecting it seem to be very important in the treatment of patients with type 1 diabetes, where insulin is the treatment of choice and dosage adjustment appears to be extremely important. Remains unknown whether the changes in the lipoprotein profile result from the beginning of insulin therapy or other factors influence it. Selecting a group of patients with less favorable lipoprotein profile may allow better metabolic control, and thus will affect the quality and length of life of our patients. These studies will assess the impact of our therapeutic actions on the diagnosis of the disease on long-term consequences, such as the development of chronic complications.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiekontakt
- Navn: Aleksandra Uruska, PhD
- Telefonnummer: +48 607620750
- E-mail: aleksandrauruska@gmail.com
Undersøgelse Kontakt Backup
- Navn: Dorota Zozulinska-Ziolkiewicz, Prof
- Telefonnummer: +48 618474579
- E-mail: kldiab@raszeja.poznan.pl
Studiesteder
-
-
-
Poznan, Polen, 60-834
- Rekruttering
- Department of Internal Medicine and Diabetiology Poznan University of Medical Sciences
-
Kontakt:
- Aleksandra Uruska, PhD
- Telefonnummer: +48 607620750
- E-mail: aleksandrauruska@gmail.com
-
Kontakt:
- Dorota Zozulinska-Ziolkiewicz, Prof
- Telefonnummer: +48 618474579
- E-mail: kldiab@raszeja.poznan.pl
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- New onset type 1 diabetes and treatment with insulin.
- Written consent to participate in the study.
- There are no other medical conditions, and with no other additional drugs beyond insulin
Exclusion Criteria:
- any other medical conditions, and any other additional drugs beyond insulin
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kun etui
- Tidsperspektiver: Fremadrettet
Kohorter og interventioner
Gruppe / kohorte |
---|
Type 1 diabetic patients
Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology.
Measurement of lipid profile and lipoproteins before and after administration of insulin.
Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in lipoproteins' metabolism
Tidsramme: Change from Baseline in lipoproteins' metabolism at 6 and 12 months
|
Evaluation of HDL levels, subfractions and enzymes connected with HDL metabolism (LCAT, lipoprotein lipase)
|
Change from Baseline in lipoproteins' metabolism at 6 and 12 months
|
Factors influencing relationship between insulin treatment and lipoproteins
Tidsramme: 1 year
|
Metabolic control, presence of remission, insulin resistance, adipokines, daily insulin requirement
|
1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in apolipoproteins
Tidsramme: Change from baseline in apolipoproteins' at 6 and 12 months
|
Evaluation of apolipoproteins: A-I, A-II, A-IV, C (II i III), D i E
|
Change from baseline in apolipoproteins' at 6 and 12 months
|
Presence of insulin resistance
Tidsramme: 1 year
|
Evaluation of lipid tissue content, VAI, triglycerides/HDL ratio and estimated glucose disposal rate
|
1 year
|
Development of Retinopathy
Tidsramme: 1 year
|
Evaluation of retinopathy (ophthalmology assessment)
|
1 year
|
Development of Neuropathy
Tidsramme: 1 year
|
Evaluation of presence of neuropathy peripheral and autonomic (clinical examination and ProsciCard)
|
1 year
|
Development of Diabetic kidney disease
Tidsramme: 1 year
|
Evaluation of presence of diabetic kidney disease (albuminuria, GFR)
|
1 year
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Generelle publikationer
- Cieluch A, Uruska A, Grzelka-Wozniak A, Niedzwiecki P, Flotynska J, Zozulinska-Ziolkiewicz D. Changes in high-density lipoprotein cholesterol (HDL-C) level and the ratio of triglycerides to HDL-C during the first year of type 1 diabetes. Pol Arch Intern Med. 2019 Sep 30;129(9):598-604. doi: 10.20452/pamw.14920. Epub 2019 Aug 5.
- Cieluch A, Uruska A, Grzelka A, Zozulinska-Ziolkiewicz D. An increase in high-density lipoprotein cholesterol concentration after initiation of insulin treatment is dose-dependent in newly diagnosed type 1 diabetes. The results of the InLipoDiab1 study. Pol Arch Intern Med. 2018 Jan 31;128(1):69-71. doi: 10.20452/pamw.4183. Epub 2018 Jan 19. No abstract available.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PoznanUMS
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 1 diabetes mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAfsluttetType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | IDDMForenede Stater, Australien
-
Capillary Biomedical, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, insulinafhængig, 1Australien
-
Spiden AGDCB Research AGRekrutteringType 1 diabetes mellitus | Type 1 diabetes mellitus med hypoglykæmi | Type 1 diabetes mellitus med hyperglykæmiSchweiz
-
Capillary Biomedical, Inc.AfsluttetType 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, type I | Diabetes mellitus, insulinafhængig, 1 | IDDMØstrig
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute...UkendtType 1 diabetes mellitus med hyperglykæmi | Type 1 diabetes mellitus med hypoglykæmiPolen
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AfsluttetType 1 diabetes mellitus | T1DM | T1D | Nyopstået type 1-diabetes mellitusForenede Stater, Australien
-
National Institute of Diabetes and Digestive and...AfsluttetDiabetes mellitus type 1Forenede Stater
-
Stem Cells ArabiaAfsluttetGlukosemetabolismeforstyrrelser | Metaboliske sygdomme | Sygdomme i immunsystemet | Autoimmune sygdomme | Sygdomme i det endokrine system | Diabetes mellitus type 1Jordan
-
Shanghai Changzheng HospitalRekrutteringSkør type 1 diabetes mellitusKina